

1 **Financial Feasibility Study and policy recommendations of Incremental Modified Drugs**
2 **Development by the Domestic Pharmaceutical Industry**

3 Manthana Laichapis^{1,2¶}, Rungpetch Sakulbumrungsil^{1*}, Khunjira Udomaksorn^{2¶}, Nusaraporn
4 Kessomboon^{3¶}, Osot Nerapusee^{1&}, Charkkrit Hongthong^{3&}, Sitanun Poonpolsub^{4&}

5

6

7

8 ¹ Department of Social and Administrative Pharmacy, Faculty of Pharmaceutical Sciences,
9 Chulalongkorn University, Thailand, Bangkok

10

11 ² Department of Social and Administrative Pharmacy, Faculty of Pharmaceutical Sciences,
12 Prince of Songkla University Thailand, Songkhla

13

14 ³ Department of Social and Administrative Pharmacy, Faculty of Pharmaceutical Sciences, Khon
15 Kaen University, Thailand, Khon Kaen

16

17 ⁴ Food and Drug Administration Thailand, Thailand, Nonthaburi

18

19 *Corresponding author

20 Email: rungpetch.c@chula.ac.th (RS)

21 ¶These authors contributed equally to this work

22 &These authors also contributed equally to this work.

23

24

25 **Abstract**

26 The Thai pharmaceutical industry aims to strengthen its drug system in accordance with
27 the National Strategic Master Plan, emphasizing sustainable development, particularly in
28 biologics and herbal products, to achieve self-reliance. Current efforts are mainly focused on
29 generic drug production, but there's a significant need for Research and Development (R&D) in
30 Innovative Medicines (IMDs). This study explores the financial feasibility of locally developing
31 an IMDs dosage form. To assess this feasibility, a mixed-methods approach was used,
32 incorporating a literature review, surveys, and interviews. This process involved selecting types
33 of IMDs, constructing financial models, determining cost structures, and conducting a thorough
34 feasibility analysis. The results indicated that a sustained-release dosage form was the most
35 viable option. The analysis took into account total development costs, payback periods, growth
36 rates, and the revenue required to recoup investments. It was found that IMD development is
37 associated with higher costs and longer durations compared to new generic drugs. The study
38 identified several challenges, such as the high cost of clinical studies, extended development
39 times, market feasibility, and drug selection difficulties. Policy recommendations were made to
40 address these challenges, including incentives for clinical studies and fostering industry expertise
41 through collaborative efforts and supportive government policies. In conclusion, the financial
42 feasibility of developing IMDs requires strategic policies and collaboration to overcome these
43 challenges and ensure sustainability. The findings of this study are intended to aid stakeholders
44 in making informed R&D investment decisions.

45

46

47 **Introduction**

48 The Thai pharmaceutical industry has focused on development in accordance with the
49 National Strategic Master Plan (2018-2037), specifically targeting the enhancement of the
50 national drug system and the potential growth of pharmaceutical manufacturing within the
51 country (1), The third national drug policy of 2011 and the national drug system development
52 strategy for 2011-2016 have emphasized the sustainable development of the pharmaceutical
53 industry, including biologics and herbal products to achieve self-reliance (2). The primary
54 objectives include the acceleration of capabilities and the elevation of the pharmaceutical
55 industry through research, development, and production of vaccines, drugs, and biologics.
56 Moreover, promoting local pharmaceutical industries and services is crucial to reduce imports
57 and increase exports.

58 Currently, the Thai pharmaceutical manufacturing industry predominantly focuses on the
59 production of generic drugs, with an average annual approval of 540 generic drugs as well as
60 new generic drugs (averaging 35 approvals per year). However, the number of new drug
61 formulations developed and approved in Thailand remains relatively small, largely because of
62 the unpreparedness of the pharmaceutical manufacturing industry and relevant regulatory
63 agencies, and the lack of explicit guidelines for the registration of new drugs produced in the
64 country. Research and development (R&D) efforts have become more focused, with the Food
65 and Drug Administration (FDA Thailand) defining seven types of new drugs: 1. New chemical
66 entities (NCEs), 2. New indications, 3. New combinations, 4. New delivery systems, 5. New
67 routes of administration, 6. New dosage forms, and 7. New strengths. Types 2-7, often referred
68 to as incrementally modified drugs or IMDs in many countries. Among these, NCEs require
69 significant investments, technology, and personnel, and Thailand currently lacks sufficient

70 capacity. Over the past decade, pharmaceutical manufacturing companies have invested in R&D
71 and adopted new technologies to develop different forms of finished products (3).

72 To support the pharmaceutical manufacturing industry, it is imperative to conduct R&D
73 on incrementally modified drugs (IMDs) that possess compounds and efficacies similar to the
74 original drugs but exhibit modified properties and characteristics. This can be achieved through
75 the use of advanced technology platforms to promote sustainable self-reliance in the Thai
76 pharmaceutical industry. Consequently, this study aims to explore the financial feasibility of
77 developing a dosage form for IMDs in the local pharmaceutical manufacturing industry. Thus, it
78 provides an investment proposal to support policymaking and investment decision-making from
79 an industrial perspective.

80 **Method**

81 The present study employed a mixed-methods approach, incorporating literature review,
82 surveys, and interviews as the qualitative part, to explore the construct of financial analysis,
83 which constitutes the quantitative part.

84 **Literature review**

85 The literature review conducted to examine the different dosage forms used in the
86 production of existing IMDs, as well as the manufacturing processes involved in IMDs, from the
87 upstream process to the downstream process. Data for the model was collected through the
88 literature review and related documents to assess the situation and ability to manufacture IMDs
89 in Thailand. An interview instrument was developed to interview relevant experts.

90 **Survey**

91 The survey method was used to identify and estimate costs based on the defined cost
92 structures, which were derived from the 'Impact of Thai-EU Free Trade Agreement (FTA)
93 concerning Intellectual Property Rights on the Pharmaceutical Supply Chain in Thailand' study
94 (Liangrokapart et al., 2013)

95 1. The collection forms with pre-defined cost structures were sent to 5 IMDs (Industrial
96 Manufacturing and Development) experts.

97 2. The experts provided estimated costs and comments to make the cost structure more
98 valid.

99 **Interview**

100 The interview process involved selecting experts and individuals with expertise in
101 assessing the situation and ability to manufacture IMDs in Thailand. The recruitment period for
102 the study spanned from August 5, 2021, to August 4, 2022. This period indicates the timeframe
103 during which participants were actively recruited and enrolled in the study.

104 A.) Demographic of informants

105 The sampling method employed for this study was the snowball sampling
106 technique until data saturation was reached. Participants were recruited from 15 local
107 pharmaceutical industry companies, of which 5 were company owners, and the remaining
108 participants were individuals associated with IMDs development.

109 B.) Interview process:

110 1. The researcher sent interview questions to research participants and schedule individual
111 online interviews. Each interview is expected to take approximately 1 hour. The
112 researcher sought permission from participants to record the interview for data analysis
113 purposes (audio recordings will be destroyed at the end of the project).

114 2. Participants' agreement to participate in the research and their decision to participate in
115 the online interview were considered as consent. Participants were not required to sign a
116 letter of consent.

117 3. Participants who complete an online interview received remuneration of 1,000 baht per
118 person.

119 C.) Question guidelines:

120 1. What are the costs associated with the research and development of a dosage form for
121 IMDs?

122 2. What are the procedures involved in the research and development of a dosage form for
123 IMDs, and what are the associated costs?

124 3. What are the costs related to manufacturing technology?

125 4. What are the costs of conducting clinical and non-clinical studies?

126 The present study employed a mixed-methods approach, incorporating literature review,
127 surveys, and interviews as the qualitative part, to explore the construct of financial analysis,
128 which constitutes the quantitative part. The methodology was adapted to perform the
129 following steps:

130 **1. Selection of IMD types**

131 Sustained release, first modified dosage form, and most preferable types of IMDs
132 were identified based on the results of a feasibility study of incrementally modified drugs
133 developed by the domestic pharmaceutical industry (4, 5).

134 **2. Development of financial models**

135 Suitable investment models were developed to align the specific circumstances
136 and capabilities of the local pharmaceutical industries.

137 **3. Identification of cost structure and cost estimation**

138 The cost structure was determined, and the costs associated with the
139 manufacturing industry's investment in IMDs were estimated. A cost structure adapted
140 from a study on the Impact of the Thai-EU Free Trade Agreement (FTA) concerning
141 Intellectual Property Rights on the Pharmaceutical Supply Chain in Thailand was applied.
142 This structure encompasses sourcing, R&D at the lab scale, pilot batch and stability
143 studies, non-clinical trials, clinical trials, registration, and process validation batch stages
144 (6). Costs were estimated based on each step of the drug development process until the
145 drug was launched in the market (7, 8).

146 **4. Financial feasibility analysis of IMDs**

147 Assumptions were set, and data related to investment variables were collected to
148 analyse the financial feasibility of IMDs. Sensitivity analysis was conducted to evaluate
149 the impact of variations in cost, duration, and payback period. Additionally, the cost was
150 estimated based on two scenarios, considering the regulatory requirements of IMDs (9).
151 The first scenario involved conducting only Phase I (scenario 1), whereas the second
152 involved conducting a full clinical trial (scenario 2).

153 **Results**

154 Based on a prediction market analysis conducted during a feasibility study of IMDs
155 development by the domestic pharmaceutical industry, the sustained-release dosage form
156 emerged as the most preferable option (4). Consequently, the financial feasibility of this
157 particular dosage form was analysed, considering the input data and assumptions outlined in
158 Table 1.

159 **Table 1** Input data and assumptions for financial model and financial feasibility study

	Details	Source of data
Cost of sales	25% of revenues	Literature review (12)
Operational expense	40% of revenues	Literature review (12), interview
Discounted rate	Discount rate 3%	Literature review (13)
Interested rate	Interest rate for business is 3%	Interview
Tax rate	Corporate tax rate is 20%	Literature review (14), interview
Expected payback period	Payback period that investors could be accepted is 5-10 years	Interview

160

161 **Model for financial feasibility analysis**

162 This study utilizes a distinct financial viability analysis model that allows investors to
163 determine the payback period and market growth rate based on a business's capacity and
164 provides valuable information for assessing the financial feasibility of investing in
165 pharmaceutical R&D. The model encompasses two main components: a cost model for
166 researching and developing the drug dosage form and a sales revenue model that calculates the
167 necessary income for capital return within the specified payback period. It offers flexibility for
168 investors to adjust variables, such as the payback period and market growth rate, aiding in the
169 decision-making process for selecting and developing study drugs.

170 **Financial feasibility analysis of sustained release dosage form**

171 Based on the information presented in Table 2, the R&D process for new
172 sustained-release forms of IMDs was found to take approximately 7 years for conducting only
173 Phase 1 clinical studies, and 11 years for the full clinical trial. By comparison, the development

174 of new generic drugs typically ranges from 25 to 46 months.(6) The longer duration in the case
175 of sustained-release forms of IMDs can be attributed to the development of new formulations,
176 higher failure rates, increased complexity of analysis, and the inclusion of clinical studies
177 involving a new drug.

178 The development of new sustained-release drugs from existing chemical entities for
179 conducting only Phase I incurs fixed costs ranging from 1.46 to 3.09 million USD. In
180 comparison, the cost of developing new generic drugs ranges from 0.19 to 1.13 million USD(6).
181 Higher costs associated with sustained-release drugs can be attributed to these factors. A
182 significant portion of the drug development costs in this scenario was allocated to process
183 validation batches, accounting for approximately 60% of the total R&D cost. This final step
184 before commercialization requires three consecutive production cycles, leading to substantial
185 capital requirements that can vary based on the complexity and ease of production.

186 In scenario with full clinical trial, which involves studying the drug from Phase 1 to
187 Phase 3 clinical trials to establish efficacy and safety, the fixed costs for new drug development
188 range from 18.60 to 20.23 million USD. Most of the cost and time in this scenario are allocated
189 to clinical trial studies, constituting approximately 70% of the total cost. Clinical trials are crucial
190 to prove the efficacy and safety of new drugs. Specific processes, sample sizes, and drug types
191 can influence R&D costs.

192 **Table 2** The process and cost of developing IMDs in the form of a sustained release by the domestic pharmaceutical industry.

Process	Details (6)	Scenario 1 (Million USD)	Scenario 2 (Million USD)	Information Source
Sourcing	Local manufacturers choose IMD reference drugs based on marketing, user needs, sales, patents, and suitability.	0.02	0.02	Interview
R&D lab scale	The R&D department conducts lab-scale studies to develop suitable formulations for sustained release drugs, including analytical method development and determination of finished product specifications (FPS).	0.06-0.15	0.06-0.15	Interview
Pilot scale	After successful drug R&D, pilot batch production begins, followed by stability studies to determine shelf-life specifications. Results are reported to FDA.	0.27-0.66	0.27-0.66	Interview
Clinical study				
-Phase I	Samples from the pilot batches production will be sent to study the effect of food on bio-efficacy through bioequivalence study and evaluating the effect of alcohol on dose dumping.	0.29	0.29	Literature review ,Interview,(9),(15)
-Phase II	In case the pharmacokinetics of a new drug are clinically significant different from the reference drug, Phase II and III studies of the new drug may be necessary.	-	4.29	Literature review ,Interview,(9)
-Phase III		-	12.86	

Registration	Registration of new drug formulas follows ASEAN Harmonization criteria. Application documents include administration data, product information, quality, safety, and efficacy parts. Non-clinical and clinical study data can refer to recommendations and guidelines.	0.003	0.003	Interview
Process validation batch	After obtaining FDA registration, drugs can be produced in commercial batches. Process validation and inspection results are submitted for permission to continue production and distribution.	0.81-1.97	0.81-1.97	Interview
Total		1.46-3.09	18.60-20.23	
Duration (years)		7	11	Interview

194 Investments in the development of new drugs from existing chemical entities incur high
195 costs. The feasibility analysis considers the costs of drug formulation development and expresses
196 them as the income that entrepreneurs should generate to achieve the capitalization point. The
197 feasibility results indicate that, for the base case analysis with an expected payback period of 5
198 years, the income required to cover the invested capital ranges from 0.20 to 1.80 million USD for
199 the scenario conducting only Phase I, and 3.01 to 27.11 million USD for the full clinical trial
200 scenario (Table 3).

201 Furthermore, with a longer duration of R&D in both scenarios, the annual income that
202 investors must generate will be higher compared with shorter time periods, indicating a higher
203 level of investment. Therefore, if entrepreneurs can expedite the R&D process, they can save
204 investment costs and increase the feasibility of developing these drugs. In cases where
205 formulation and analytical method development carry a high risk of failure and involve
206 numerous areas of development, including more sophisticated clinical studies, investing in R&D
207 processes may require higher capital investment, and investors need to generate higher income to
208 achieve a higher capitalization point.

209 Considering the payback period for investors, longer payback periods tend to result in a
210 lower capitalization point, requiring lower annual income generation by operators, compared to
211 shorter payback periods. If a drug has a longer lifecycle and does not require frequent
212 development, such as drugs for chronic diseases, a longer acceptable payback period may be
213 applicable.(10) Various factors, including the annual sales growth rate, marketability upon
214 launch, number of competitors, and government policies, influence feasibility assessment.

215 **Table 3** The feasibility study results of this study show in terms of income that
 216 investors should be able to achieve in order to achieve capital gains.

	Scenario 1 (Million USD)	Scenario 2 (Million USD)
Payback period		
5 years payback period	0.20-1.80*	3.01-27.11**
10 years payback period	0.04-1.20	0.63-17.87
Duration of research and development		
Scenario 1		
5 years	0.18-1.66	
10 years	0.26-2.33	
Scenario 2		
10 years	2.85-25.63	
15 years	4.19-37.73	

217 * The parameters of scenario 1 base case analysis are that the duration of research and development is 7 years,
 218 and the research and development cost is 1.46 million USD.

219 ** The parameters of scenario 2 base case analysis are that the duration of research and development is 11
 220 years, and the research and development cost is 18.60 million USD

221

222 Discussion

223 This study conducted a financial feasibility analysis, specifically focusing on sustained-
224 release dosage forms, which differ from other financial models. The analysis estimated four key
225 constructs: the total cost of IMD development, expected payback period, expected growth rate,
226 and expected revenue that investors could potentially earn to cover the break-even point or
227 generate profit. However, these dosage forms may vary in their active ingredients, making it
228 challenging to estimate sales revenue and market growth without precise information regarding
229 the specific active ingredients being developed for the studied drug form. The methodology
230 chosen in this study is suitable for analyzing the financial aspects of new drugs or innovations
231 despite limited data availability. To strengthen the reliability of the limited data, the triangulation
232 method was employed, enhancing the validity and credibility of the findings.

233 The findings from each scenario indicate that investments in IMDs are relatively high and
234 require a longer development duration than new generic drugs. A major portion of these
235 investments is attributed to conducting clinical studies for registration, drug selection, and the
236 sufficiency of presented data to confirm efficacy and safety. Financial feasibility considerations
237 are also influenced by an entrepreneur's capacity to invest and generate income.

238 This study identifies key factors that can potentially affect investors' decision-making
239 processes. First, clinical studies play a crucial role in drug development and contribute
240 significantly to the overall cost. Challenges, such as limited clinical data from reference products
241 and complexities associated with different types of IMDs, along with drug properties, such as
242 pharmacodynamics, pharmacokinetics, and toxicity, can drive the investment required for this
243 phase. Consequently, this cost burden can impact investors' decisions and hinder the
244 development of new drugs in the domestic pharmaceutical industry. When it is not feasible to

245 bridge clinical study data from a previous product to support the development of a new drug,
246 conducting a clinical study becomes imperative.(9) Offering incentives and support to conduct
247 clinical studies, particularly for IMDs, can alleviate the financial burden on pharmaceutical
248 companies. These incentives may include grants, tax benefits, or expedited regulatory processes.
249 In such cases, an alternative strategy could involve considering clinical trials in countries with
250 high overall attractiveness indices(11). In doing so, the aim is to expedite the drug's path to the
251 market, ultimately accelerating the return on investment and potentially gaining a competitive
252 edge over other market players.

253 Second, the development of IMDs in domestic industry is still relatively new, resulting in
254 longer development times and increased costs. One key factor contributing to this extended
255 duration is the limited knowledge and expertise within the domestic industry and related
256 organizations. Additionally, the conducting of clinical trials and challenges in the registration
257 system can add to the overall time required for the development of an IMDs. To mitigate these
258 challenges and shorten the duration of development, it is essential to focus on building capacity
259 among all stakeholders involved in the process by establishing comprehensive capacity-building
260 programs to enhance expertise within the domestic pharmaceutical industry and related
261 organizations. These programs should focus on improving proficiency in the R&D processes,
262 conducting efficient clinical trials, and navigating regulatory procedures. By implementing such
263 initiatives, the duration of the IMDs development can be reduced, resulting in cost savings.
264 Furthermore, it is crucial to recognize that the R&D process for IMDs should commence early
265 during the originator-branded product lifecycle. Since IMDs development can be time-
266 consuming, starting the R&D process early ensures sufficient time for thorough research, testing,
267 and regulatory processes.

268 Third, owing to the high investment required to reach the capital break-even point and
269 generate profits, entrepreneurs need to consider market feasibility and potential sales
270 opportunities for IMDs. The presence of generic and new generic drugs as competitors in the
271 market increases the complexity. To promote the adoption of IMDs, the government and
272 associated organizations can play a role by proposing supportive policies as well as supporting
273 export policies to expand market opportunities. Collaborative efforts involving the public and
274 private sectors are crucial for sustainable development of the domestic pharmaceutical industry.

275 Fourth, the process of selecting suitable drugs for IMDs development involves careful
276 consideration of various factors including financial aspects, patient needs, scientific and
277 technological feasibility, and legal and registration feasibilities. It is crucial to acknowledge that
278 not every drug can be formulated in every dosage form, which makes the drug selection process
279 a significant factor that influences investment decisions. Several key elements are involved in
280 drug selection. Market competitors and the expected payback period that the pharmaceutical
281 industry can accept play crucial roles in determining the feasibility of drugs for IMD
282 development. For instance, drugs such as antibiotics may require shorter payback periods owing
283 to the potential emergence of drug resistance, whereas drugs used to treat chronic diseases or
284 orphan drugs may require longer payback periods. In this context, selecting drugs with longer
285 lifecycles and those that already possess sufficient existing data for bridging may be more
286 feasible investment options. These drugs are more likely to have sustainable market demand and
287 provide a higher chance of success in the development process.

288 By adopting and implementing these policy recommendations, the government and
289 associated organizations can establish an enabling environment for the development of IMDs,

290 foster innovation, reduce costs, and ensure long-term sustainability of the domestic
291 pharmaceutical industry.

292 **Conclusions**

293 This study provides crucial insights into the financial feasibility of developing sustained
294 release dosage forms for IMDs in the Thai pharmaceutical industry. The proposed policy
295 recommendations aim to create an enabling environment for IMDs development, ultimately
296 fostering innovation and ensuring the sustainability of the domestic pharmaceutical industry.

297 **Acknowledgements**

298 The authors would like to express my sincere gratitude to the Thai Pharmaceutical
299 Manufacturers Association (TPMA) for their excellent collaboration, which allowed us to
300 conduct interviews and gather valuable data for the assessment. Our deepest appreciation goes
301 to all the participants who generously gave their time and contributed to this study. Their active
302 participation and valuable insights greatly enriched our research.

303 **References**

- 304 1. Secretariat of the National Strategy Committee. The National strategy of THAILAND
305 (2018 - 2037) 2016;4.
- 306 2. National drug system development committee. national drug policy 2011 and national
307 drug system development strategy 2011-2016. 2011.
- 308 3. Committee on Thai drug system. Thai drug system 2020. Health system research
309 institute2020.

- 310 4. Sakulbumrungsil R, Kessomboon N, Udomaksorn K, Poonpolsub S, Nerapusee O,
311 Hongthong C, et al. Feasibility Study of Dosage Form Drug Development for Incrementally
312 Modified by Domestic Pharmaceutical Industry. 2022.
- 313 5. Hongthong C, Sakulbumrungsil R, Udomaksorn K, Poonpolsub S, Nerapusee O,
314 Laichapis M, et al. Feasibility study of sustained release dosage forms for incrementally
315 modified drug by domestics pharmaceutical industry in Thailand [version 1; peer review:
316 awaiting peer review]. F1000Research. 2023;12(1513).
- 317 6. Liangrokapart J, Kessomboon N, Sakulbumrungsil R, Akaleephan C, Poonpolsub S,
318 Saerekul P. Impact of Thai-EU Free Trade Agreement (FTA) concerning Intellectual Property
319 Rights on the Pharmaceutical Supply Chain in Thailand. 2013.
- 320 7. Tamplin T. Classification of Cost [https://learn.financestrategists.com/explanation/cost-](https://learn.financestrategists.com/explanation/cost-accounting/analysis-of-cost/classification-of-cost/)
321 [accounting/analysis-of-cost/classification-of-cost/](https://learn.financestrategists.com/explanation/cost-accounting/analysis-of-cost/classification-of-cost/): finance strategists; 2021.
- 322 8. E-finance management. Classification of Costs based on Functions / Activities
323 [https://efinancemanagement.com/costing-terms/classification-of-costs-based-on-functions-](https://efinancemanagement.com/costing-terms/classification-of-costs-based-on-functions-activities2021)
324 [activities2021](https://efinancemanagement.com/costing-terms/classification-of-costs-based-on-functions-activities2021) .
- 325 9. Thai food and drug administration. Guideline for nonclinical and clinical evaluations of
326 new drug products from previously approved drug substances. In: Bureau D, editor. 2019.
- 327 10. Teramae F, Makino T, Sengoku S, Lim Y, Natori T, Kodama K. Research on
328 Pharmaceutical Product Life Cycle Patterns for Sustainable Growth. Sustainability.
329 2020;12(21):8938.
- 330 11. Bailey W, Cruickshank C, Sharma N. Make your move: taking clinical trials to the best
331 location.

332 12. Jiang J, Kong J. how did the public U.S. drugmakers' sales, expenses and profit change
333 over time ? : USC Leonard D. Schaeffer Center for Health Policy & Economics; 2021 [Available
334 from: [https://healthpolicy.usc.edu/evidence-base/how-did-the-public-u-s-drugmakers-sales-
335 expenses-and-profits-change-over-time/](https://healthpolicy.usc.edu/evidence-base/how-did-the-public-u-s-drugmakers-sales-expenses-and-profits-change-over-time/).

336 13. Haacker M, Hallett TB, Atun R. On discount rates for economic evaluations in global
337 health. Health Policy Plan. 2020;35(1):107-14.

338 14. Department of industries ministry of economic affairs royal government of Bhutan.
339 Feasibility analysis of drug formulation. IDRG consultancy services; 2009.

340 15. National Institute on Aging. What Are Clinical Trials and Studies? : National Institute on
341 Aging; 2023 [Available from: [https://www.nia.nih.gov/health/what-are-clinical-trials-and-
342 studies#:~:text=Clinical%20trials%20are%20research%20studies,safe%20and%20effective%20i
343 n%20people](https://www.nia.nih.gov/health/what-are-clinical-trials-and-studies#:~:text=Clinical%20trials%20are%20research%20studies,safe%20and%20effective%20in%20people).

344

345

346

347

348